Prestige Consumer Healthcare Inc. (PBH) - Q3 2026 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended December 31, 2025 (Q3 of Fiscal Year 2026). Prestige Consumer Healthcare Inc. develops, manufactures, and distributes over-the-counter (OTC) health and personal care products in North America, Australia, and other international markets. The company operates through two segments: North American OTC Healthcare and International OTC Healthcare.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenues | $283.4 million | $290.3 million | $807.1 million | $841.2 million |
| Net Income | $46.7 million | $61.0 million | $136.4 million | $164.5 million |
| Diluted EPS | $0.97 | $1.22 | $2.78 | $3.28 |
| Gross Margin | 55.5% | 55.5% | 55.7% | 55.2% |
| Operating Income | $82.5 million | $92.0 million | $233.9 million | $248.3 million |
| Operating Cash Flow (YTD) | $214.8 million (vs. $189.7 million YTD 2024) | |||
| Long-Term Debt | $1.04 billion (includes $40M revolver draw) | |||
| Cash & Equivalents | $62.4 million (as of Dec 31, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 2.4% in Q3 and 4.1% YTD compared to the prior year. The decline was driven primarily by the Eye & Ear Care category (down 9.5% in Q3, 21.9% YTD) due to supply shortages of Clear Eyes products.
- Unusual Item: The company recorded a $10.3 million non-cash write-off of a supplier loan included in "Other expense, net" for both the quarter and YTD periods.
- Acquisition: On December 18, 2025, the company acquired Pillar5 Pharma, Inc. for approximately $111.9 million to secure sterile ophthalmic manufacturing capacity. This was funded by cash and a $40 million draw on the revolving credit facility.
- Share Repurchases: The company repurchased approximately $155.6 million of common stock YTD 2025, compared to $40.2 million in the prior year period. Approximately $92.9 million remains available under the current authorization.
- Tax Rate Increase: The effective tax rate increased to 29.2% YTD 2025 from 21.8% YTD 2024, primarily due to establishing a taxable presence in a new state.
Outlook, Risks, and Management Commentary
- Supply Chain Constraints: Management highlights ongoing volatility in the global supply chain, including labor shortages and raw material cost increases. Shortages of eye care products continue to negatively impact sales, and further disruptions are expected.
- Economic Environment: The company notes high inflation, geopolitical events, and trade restrictions as factors that could pressure prices and demand. Consumer purchasing patterns are shifting toward online channels.
- Liquidity: The company maintains $146.4 million in borrowing capacity on its revolver and believes cash from operations and existing facilities are sufficient for the next 12 months. It remains in compliance with all debt covenants.
- Guidance: The filing does not provide specific numerical guidance for the full fiscal year 2026, noting that interim results are not necessarily indicative of future performance.
Key Facts for Investor Verification
- Supply Chain Resolution: Verify the timeline for resolving Clear Eyes supply shortages and the impact of the Pillar5 acquisition on future inventory levels.
- Supplier Loan Write-off: Confirm the nature of the $10.3 million supplier loan write-off and assess if there are other potential receivables at risk.
- Customer Concentration: Walmart and Amazon accounted for approximately 18% and 19% of Q3 revenues, respectively. Monitor any changes in retailer purchasing patterns or shelf-space demands.
- Debt Servicing: With $1.04 billion in debt and a fixed charge ratio covenant, monitor interest rate impacts and cash flow sufficiency for debt service.
- Intangible Asset Valuation: Given the heavy reliance on goodwill and intangibles ($2.3 billion net), monitor for potential future impairment charges if sales or margins decline further.